[Usefulness of Immunostaining Scoring for Predicting Response to Single-Agent Nivolumab in Patients with Metastatic Renal Cell Carcinoma].
Hinyokika Kiyo
; 68(10): 311-315, 2022 Oct.
Article
in Ja
| MEDLINE
| ID: mdl-36329378
Full text:
1
Database:
MEDLINE
Main subject:
Carcinoma, Renal Cell
/
Antineoplastic Agents, Immunological
/
Kidney Neoplasms
Type of study:
Prognostic_studies
/
Risk_factors_studies
Limits:
Humans
Language:
Ja
Journal:
Hinyokika Kiyo
Year:
2022
Type:
Article